Patient characteristics
| Variable . | Total (N = 138) . |
|---|---|
| Age, y, median [Q1;Q3] | 66 [56;80] |
| Men/women (n) | 61/77 |
| Charlson comorbidity index >1, n (%) | 28 (20.2) |
| Months with ITP, median [Q1;Q3] | 51 [10;165] |
| Platelet count at diagnosis, median [Q1;Q3], ×109/L | 13 [5;26] |
| Bleeding at diagnosis, n (%) | 95 (68.8) |
| Type of primary ITP, n (%) | 122 (88.4) |
| Newly diagnosed | 15 (12.3) |
| Persistent | 21 (17.2) |
| Chronic | 86 (70.5) |
| Type of secondary ITP, n (%) | 16 (11.6) |
| Neoplastic disease | 7 (43.7) |
| Autoimmune disorders | 4 (25) |
| Immunodeficiencies | 3 (18.8) |
| Viral infections | 1 (6.2) |
| Evans syndrome | 1 (6.2) |
| Past ITP treatments, median [Q1;Q3] | 4 [2;5] |
| Eltrombopag, n (%) | 105 (76.1) |
| Romiplostim, n (%) | 79 (57.2) |
| IVIG, n (%) | 61 (44.2) |
| Rituximab, n (%) | 40 (29.0) |
| Splenectomy, n (%) | 19 (13.8) |
| Avatrombopag, n (%) | 13 (9.4) |
| Platelet count at fostamatinib treatment initiation, median [Q1;Q3], ×109/L | 21 [8;47] |
| Bleeding at fostamatinib treatment initiation, n (patients; %) | 58 (42.0) |
| Bruising, n (episodes; %) | 39 (28.3) |
| Petechiae, n (episodes; %) | 32 (23.2) |
| Epistaxis, n (episodes; %) | 6 (4.3) |
| Gingivorrhages, n (episodes; %) | 6 (4.3) |
| Bullae in oral cavity, n (episodes; %) | 5 (3.6) |
| Digestive bleeding (high or low), n (episodes; %) | 4 (2.9) |
| Menorrhagia, n (episodes; %) | 2 (1.45) |
| Hematuria, n (episodes; %) | 1 (0.72) |
| Bleeding episodes during fostamatinib treatment, n (patients; %) | 20 (14.5) |
| Bruising, n (episodes; %) | 12 (8.7) |
| Petechiae, n (episodes; %) | 10 (7.2) |
| Epistaxis, n (episodes; %) | 5 (3.6) |
| Gingivorrhages, n (episodes; %) | 3 (2.1) |
| Bullae in oral cavity, n (episodes; %) | 3 (2.1) |
| Digestive bleeding (high or low), n (episodes; %) | 2 (1.45) |
| Menorrhagia, n (episodes; %) | 1 (0.72) |
| Concomitant treatment, n (%) | 56 (40.6) |
| Corticoids | 25 (44.6) |
| Romiplostim | 5 (8.6) |
| Corticoids plus romiplostim | 5 (8.6) |
| Immunoglobulins | 4 (7.1) |
| Corticoids plus immunoglobulins | 4 (7.1) |
| Eltrombopag | 3 (5.3) |
| Avatrombopag | 3 (5.3) |
| Triple drug combinations | 2 (3.5) |
| Corticoids plus other different drugs | 2 (3.5) |
| Variable . | Total (N = 138) . |
|---|---|
| Age, y, median [Q1;Q3] | 66 [56;80] |
| Men/women (n) | 61/77 |
| Charlson comorbidity index >1, n (%) | 28 (20.2) |
| Months with ITP, median [Q1;Q3] | 51 [10;165] |
| Platelet count at diagnosis, median [Q1;Q3], ×109/L | 13 [5;26] |
| Bleeding at diagnosis, n (%) | 95 (68.8) |
| Type of primary ITP, n (%) | 122 (88.4) |
| Newly diagnosed | 15 (12.3) |
| Persistent | 21 (17.2) |
| Chronic | 86 (70.5) |
| Type of secondary ITP, n (%) | 16 (11.6) |
| Neoplastic disease | 7 (43.7) |
| Autoimmune disorders | 4 (25) |
| Immunodeficiencies | 3 (18.8) |
| Viral infections | 1 (6.2) |
| Evans syndrome | 1 (6.2) |
| Past ITP treatments, median [Q1;Q3] | 4 [2;5] |
| Eltrombopag, n (%) | 105 (76.1) |
| Romiplostim, n (%) | 79 (57.2) |
| IVIG, n (%) | 61 (44.2) |
| Rituximab, n (%) | 40 (29.0) |
| Splenectomy, n (%) | 19 (13.8) |
| Avatrombopag, n (%) | 13 (9.4) |
| Platelet count at fostamatinib treatment initiation, median [Q1;Q3], ×109/L | 21 [8;47] |
| Bleeding at fostamatinib treatment initiation, n (patients; %) | 58 (42.0) |
| Bruising, n (episodes; %) | 39 (28.3) |
| Petechiae, n (episodes; %) | 32 (23.2) |
| Epistaxis, n (episodes; %) | 6 (4.3) |
| Gingivorrhages, n (episodes; %) | 6 (4.3) |
| Bullae in oral cavity, n (episodes; %) | 5 (3.6) |
| Digestive bleeding (high or low), n (episodes; %) | 4 (2.9) |
| Menorrhagia, n (episodes; %) | 2 (1.45) |
| Hematuria, n (episodes; %) | 1 (0.72) |
| Bleeding episodes during fostamatinib treatment, n (patients; %) | 20 (14.5) |
| Bruising, n (episodes; %) | 12 (8.7) |
| Petechiae, n (episodes; %) | 10 (7.2) |
| Epistaxis, n (episodes; %) | 5 (3.6) |
| Gingivorrhages, n (episodes; %) | 3 (2.1) |
| Bullae in oral cavity, n (episodes; %) | 3 (2.1) |
| Digestive bleeding (high or low), n (episodes; %) | 2 (1.45) |
| Menorrhagia, n (episodes; %) | 1 (0.72) |
| Concomitant treatment, n (%) | 56 (40.6) |
| Corticoids | 25 (44.6) |
| Romiplostim | 5 (8.6) |
| Corticoids plus romiplostim | 5 (8.6) |
| Immunoglobulins | 4 (7.1) |
| Corticoids plus immunoglobulins | 4 (7.1) |
| Eltrombopag | 3 (5.3) |
| Avatrombopag | 3 (5.3) |
| Triple drug combinations | 2 (3.5) |
| Corticoids plus other different drugs | 2 (3.5) |